JZJiuyi Zheng

Jiuyi Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiuyi Zheng has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Gang Chen

    Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

    3 shared publications
  • Yi Wang

    Department of Epidemiology and Biostatistics, School of Public Health and Management, Wenzhou Medical University, Wenzhou, People’s Republic of China

    2 shared publications
  • Bangjie He

    Department of Hepatobiliary Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou People's Republic of China

    1 shared publication
  • Chang Sik Yu

    Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    1 shared publication
  • Chongming Zheng

    Department of Hepatobiliary Surgery The First Affiliated Hospital of Wenzhou Medical University Wenzhou People's Republic of China

    1 shared publication
  • Daojie Wang

    College of Agriculture, State Key Laboratory of Crop Stress Adaptation and Improvement, Henan University, Kaifeng, China

    1 shared publication

Latest Publications

  • Open Access

    Synergistic Effect of Lenvatinib and Chemotherapy in Hepatocellular Carcinoma Using Preclinical Models

    by Mingxun Wang, Xinfei Yao, Zhiyuan Bo, Jiuyi Zheng, Haitao Yu, Xiaozai Xie, Zixia Lin, Yi Wang, Gang Chen, Lijun Wu

    Purpose: The current study aimed to evaluate the synergistic efficacy of lenvatinib and FOLFOX (infusional fluorouracil (FU), folinic acid, and oxaliplatin) in hepatocellular carcinoma (HCC) using patient-derived xenograft (PDX) and PDX-derived organotypic spheroid (XDOTS) models in vivo and in vitro. Methods: PDX and matched XDOTS models originating from three patients with HCC were established. All models were divided into four groups and treated with drugs alone or in combination. Tumor growth in the PDX models was measured and recorded, and angiogenesis and phosphorylation of the vascular endothelial growth factor receptor (VEGFR2), rearranged during transfection (RET), and extracellular signal-regulated kinase (ERK) were detected using immunohistochemistry and Western blot assays. The proliferative ability of XDOTS was evaluated through active staining and immunofluorescence staining, and the effect of the combined medication was evaluated using the Celltiter-Glo luminescent cell viability assay. Results: Three PDX models with genetic characteristics similar to those of the original tumors were successfully established. Combining lenvatinib with FOLFOX led to a higher tumor growth inhibition rate than individual therapies (P < 0.01). Immunohistochemical analysis demonstrated that the combined treatment significantly inhibited the proliferation and angiogenesis of PDX tissues (P < 0.05), and Western blot analysis showed that the combined treatment significantly inhibited the phosphorylation of VEGFR2, RET, and ERK compared with single-agent treatment. Additionally, all three matched XDOTS models were successfully cultured with satisfactory activity and proliferation, and the combined therapies led to better suppression of XDOTS growth compared with individual therapy (P < 0.05). Conclusion: Lenvatinib combined with FOLFOX had a synergistic antitumor effect in HCC PDX and XDOTS models by inhibiting the phosphorylation of VEGFR, RET, and ERK.


  • Prognostic value of diffuse reduction of spleen density on postoperative survival of pancreatic ductal adenocarcinoma: A retrospective study

    by Jiuyi Zheng, Bangjie He, Liming Deng, Xuewen Zhu, Rizhao Li, Kaiyu Chen, Chongming Zheng, Daojie Wang, Yi Wang, Chang Yu, et al.

    It is difficult to predict the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) before radical operation. The purpose of this study was to explore the connection between the diffuse reduction of spleen density on computed tomography (DROSD) and the postoperative prognosis of patients with PDAC. A total of 160 patients with PDAC who underwent radical surgery in the First Affiliated Hospital of Wenzhou Medical University were enrolled. Cox regression analysis was used to cast the overall survival (OS) and evaluate the prognostic factors. Nomogram was used to forecast the possibility of 1-year, 3-year, and 5-year OS. The prediction accuracy and clinical net benefit are performed by concordance index (C-index), calibration curve, time-dependent receiver operating characteristics (tdROC), and decision curve analysis. In multivariable Cox analysis, DROSD is independently related to OS. Advanced age, TNM stage, neutrophil/lymphocyte ratio, and severe complications were also independent prognostic factors. The calibration curves of nomogram showed optimal agreement between prediction and observation. The C-index of nomogram is 0.662 (95%CI, 0.606-0.754). The area under tdROC curve for a 3-year OS of nomogram is 0.770. DROSD is an independent risk factor for an OS of PDAC. We developed a nomogram that combined imaging features, clinicopathological factors, and systemic inflammatory response to provide a personalized risk assessment for patients with PDAC.


  • ZIC2 promotes colorectal cancer growth and metastasis through the TGF-β signaling pathway

    by Fangting Liu, Zhehao Shi, Wenming Bao, Jiuyi Zheng, Kaiyu Chen, Zhihui Lin, Hao-Nan Song, Xin Luo, Qiantong Dong, Lei Jiang, et al.